Skip to Main Content

The Tesaro takeout rumors turned out to be true.

The cancer-focused biotech is being acquired by pharma giant GlaxoSmithKline for $5.1 billion, the companies announced Monday. The deal values Tesaro at $75 per share, or a 63 percent premium to Friday’s closing price.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!